The HMGB3 knockout HeLa polyclonal cells constitute a CRISPR/Cas9-edited population with heterogeneous gene disruptions, enabling functional ablation of the chromatin regulator HMGB3. This polyclonal format preserves the intrinsic heterogeneity of cancer cells while providing consistent target gene depletion, making it ideal for loss-of-function studies in a well-established epithelial carcinoma model. The knockout approach facilitates investigation of HMGB3??s nuclear functions without clonal selection bias.
HeLa cells, derived from a human cervical adenocarcinoma and transformed by HPV18, are a classic model for studying HPV-driven oncogenesis. The viral E6 and E7 oncoproteins inactivate p53 and Rb, respectively, creating a background permissive for exploring additional oncogenic drivers like HMGB3. These adherent cells exhibit robust growth and are widely used in signal transduction and drug response assays. As a polyclonal knockout derivative, these cells offer a genetically perturbed system without monoclonal limitation.
HMGB3 is a non-histone chromatin protein that regulates DNA architecture and transcription. It is induced by the ??-catenin/TCF complex, activated by p53 and NF-??B, and drives expression of MMP2, MMP9, Cyclin D1, c-Myc, and Snail. HMGB3 directly binds DNA, histones, p53, and RAG1/RAG2, and it enhances Wnt/??-catenin and NF-??B signaling while repressing p53-mediated apoptosis. Within the Wnt pathway, the ??-catenin/TCF4/LEF1 complex transcriptionally induces HMGB3, which then promotes pro-proliferative and pro-invasive gene programs.
In HeLa cells with compromised p53 and Rb, HMGB3 knockout clarifies its role in p53-independent tumor maintenance and cooperation with viral oncoproteins. Overexpressed in multiple cancers, HMGB3 is a valuable target; this polyclonal knockout enables dissection of its contributions to proliferation, migration, and DNA repair in an epithelial context. The model is ideal for analyzing HMGB3??s interaction with ??-catenin/TCF and NF-??B cascades and for evaluating Wnt-driven transcriptional dependencies under compromised tumor suppressor checkpoints.
Applications include MTT and colony formation proliferation assays, Transwell migration/invasion assays, and RT-qPCR profiling of downstream targets like MMP2 and c-Myc. The cells support ChIP-qPCR for HMGB3?CDNA binding, immunofluorescence localization, and reporter assays for Wnt/??-catenin and NF-??B activity. They are also suitable for drug target validation, Annexin V apoptosis studies, and synthetic lethality screens. For further information and ordering, contact Ascent Research.
